Episode
Shalin Shah - CEO of Marius Pharmaceuticals on the oral TRT partnership with Hims
- Podcast
- Hims House
- Published
- Nov 10, 2025
- Duration seconds
- 1955
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/hims-house-7026583/episodes/shalin-shah-ceo-of-marius-pharmaceuticals-on-the-oral-trt-partnership-with-hims/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/hims-house-7026583/shalin-shah-ceo-of-marius-pharmaceuticals-on-the-oral-trt-partnership-with-hims.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Shalin Shah is the founder & CEO of Marius Pharmaceuticals, the company that partnered with $HIMS to launch oral testosterone (KYZATREX). We discuss how the partnership came about, the benefits of teaming up with $HIMS, and the future of TRT. (00:41) Origin of the partnership (02:55) Benefits of partnering with $HIMS (04:14) Deal shape and exclusivity (06:51) How KYZATREX will sit alongside compounded meds on the $HIMS platform (09:22) Will KYZATREX be personalized? (16:07) TRT as a schedule 3 substance (21:39) Gearing up for 2026 launch of KYZATREX (22:40) Future of TRT market (27:29) Peptides (29:44) Testosterone for females Get full access to Hims House at himshouse.substack.com/subscribe